ASH Sickle Cell Guidelines: Stem Cell Transplantation

Over recent years, growing experience with allogeneic hematopoietic stem cell transplantation (HSCT) has underscored its role as the only currently available potentially curative therapy for sickle cell disease (SCD), while also highlighting important risks that must be carefully weighed against standard disease-modifying and supportive treatments. The ASH Clinical Practice Guidelines on SCD: Stem Cell Transplantation provide evidence-based recommendations to help clinicians and individuals with SCD determine who should be considered for HSCT, when in the disease course to pursue transplant, and how donor options influence decision-making.